Evidence map›Paper›PMID 39237502›Full record

Trial reportBlood cancer journal2024

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

Ricardo D Parrondo, Betsy R LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J Flott, Diedre Arrington, Dustin Chapin, Jade Brown, Saurav Das, Vivek Roy and 2 more

Abstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ricardo D ParrondoDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.ORCID 0000-0002-9314-9933
Betsy R LaPlantQuantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Jamie ElliottDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Andre FernandezDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Caitlin J FlottDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Diedre ArringtonDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Dustin ChapinDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Jade BrownDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Saurav DasDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.ORCID 0000-0003-0597-8123
Vivek RoyDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.ORCID 0000-0002-5950-4620
Asher A Chanan-KhanDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA.
Sikander AilawadhiDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Jacksonville, FL, USA. Ailawadhi.Sikander@mayo.edu.ORCID 0000-0002-8377-8111

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneMultiple MyelomaThalidomideAgedAntibodies, MonoclonalDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizeddaratumumabDexamethasoneelotuzumabpomalidomideThalidomide

Identifiers

PMID39237502
PMCPMC11377826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.